Zacks Investment Research downgraded Zoetis Inc (NYSE:ZTS) to Hold in a report released earlier today.
- Updated: October 6, 2016
Yesterday Zoetis Inc (NYSE:ZTS) traded -1.43% lower at $51.60. ZTS’s 50-day average is $51.28 and its two hundred day average is $48.65. With the last close up 5.72% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Volume of trade was down over the average, with 1,524,922 shares of ZTS changing hands under the typical 3,227,640
Zacks Investment Research has downgraded Zoetis Inc (NYSE:ZTS) to Hold in a report released on 10/06/2016.
With a total market value of $0, Zoetis Inc has PE ratio of 40.06 with a one year low of $38.26 and a one year high of $52.64 .
A total of 10 firms have released a research note on ZTS. 0 brokerages rating the stock a strong buy, zero analysts rating the stock a buy, 0 brokers rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 analysts rating the company a sell with a 12-month price target of $52.70.
More About Zoetis Inc (NYSE:ZTS)
Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. It operates through two segments: the United States and International. Within each of these segments, it offers a diversified product portfolio for both livestock and companion animal customers. In addition, its Client Supply Services (CSS) organization provides contract manufacturing services to third parties. It also offers other product categories, such as nutritionals and agribusiness.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.